- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01806441
Impact of a Short-Term High Fat or Low Fat Diet on Intestinal Genes Expression Involved in the Cholesterol and Fatty Acid Metabolism (DGENES)
March 5, 2013 updated by: Patrick Couture, Laval University
Impact of a Short-Term High Fat Diet Versus A Short-Term Low Fat Diet on Expression of the Key Intestinal Genes Involved in the Cholesterol and Fatty Acid Metabolism Pathways
Dietary fat has been shown to modulate cholesterol and fatty acids homeostasis and several lines of evidence suggest that this effect is associated with changes in the regulation of different genes at the intestine level involved in the cholesterol and fatty acid metabolism pathways.
The present study will examine the impact of a short-term high fat diet versus a short-term low fat diet on expression of Niemann-Pick C1-like 1 (NPC1L1), adenosine triphosphate (ATP) binding cassette transporters (ABCG5/8), microsomal triglyceride transfer protein (MTP) and fatty acid transport protein-4 (FATP4), which have been shown to play a critical role in intestinal cholesterol absorption, chylomicron synthesis and dietary lipid absorption.
Gene expression studies will be performed on duodenal biopsies.
The primary hypothesis is that a short-term high fat diet will significantly decrease duodenal messenger ribonucleic acid (mRNA) levels of NPC1L1, ABCG5/8, MTP and FATP4 as compared with a short-term low fat diet.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Quebec
-
Quebec city, Quebec, Canada, G1V 0A6
- Institute of nutrition and functional food
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Males 18 to 50 years of age
- Non-smoker
- Body mass index between 20.0 and 30.0 kg/m2
- Plasma LDL-cholesterol levels between the 25th and 75th percentile for their age at day -14
- Plasma triglyceride levels < 1.7 mmol/L (150 mg/dl) at day -14
- Plasma HDL-cholesterol levels between 0.9 (35 mg/dl) and 1.6 mmol/L (60 mg/dl) at day -14
- Subjects must be willing to give written informed consent and able to adhere to the diet schedule and visit schedule
- Patients should be otherwise healthy, without elevations in hepatic transaminases or creatine kinase (CK) or abnormal renal function or coagulation
Exclusion Criteria:
- Patients with extreme dyslipidemias, such as familial hypercholesterolemia will be excluded
- Subjects will be excluded if they have cardiovascular disease (CHD, cerebrovascular disease or peripheral arterial disease) or if they are taking other medications known to affect lipoprotein metabolism (eg. steroids, beta blockers, thiazide diuretics, other lipid lowering agents, significant alcohol intake etc.)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 3-days high fat diet
During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).
|
During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).
|
|
Active Comparator: 3-days low fat diet
During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
|
During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in duodenal mRNA expression of NPC1L1, ABCG5/8, MTP and FATP4.
Time Frame: At the end of the two 3-days diets (day 3 and day 17).
|
Six biopsies (3 X 3 mm) will be obtained from the second portion of the duodenum during gastro-duodenoscopy.
Biopsy specimen will be stored at -86°C before mRNA extraction.
Total RNA will be isolated and used for polymerase chain reaction (PCR) quantification.
|
At the end of the two 3-days diets (day 3 and day 17).
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in surrogate markers of cholesterol absorption and synthesis.
Time Frame: At the end of the two 3-days diets (day 3 and day 17).
|
At the end of the two 3-days diets (day 3 and day 17).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Patrick Couture, MD,FRCP,PhD, Laval University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2009
Primary Completion (Actual)
May 1, 2009
Study Completion (Actual)
December 1, 2010
Study Registration Dates
First Submitted
March 4, 2013
First Submitted That Met QC Criteria
March 5, 2013
First Posted (Estimate)
March 7, 2013
Study Record Updates
Last Update Posted (Estimate)
March 7, 2013
Last Update Submitted That Met QC Criteria
March 5, 2013
Last Verified
March 1, 2013
More Information
Terms related to this study
Other Study ID Numbers
- INAF-125-05-06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gene Expression
-
Centre Leon BerardRecruitingCancer | Cancer Metastatic | ALK Fusion Protein Expression | FGFR2 Gene Translocation | FGFR3 Gene Translocation | NTRK Family Gene Mutation | Gene Fusion | ROS1 Gene Translocation | NTRK Gene Fusion Overexpression | ATIC-ALK Fusion Protein Expression | BCR-FGFR1 Fusion Protein Expression | COL1A1-PDGFB Fusion... and other conditionsFrance, Denmark, Netherlands, Austria, Germany, Italy, United Kingdom, Czechia, Poland, Slovenia, Spain
-
Galderma R&DCompletedGene ExpressionUnited States
-
University of California, Los AngelesCompleted
-
Ullevaal University HospitalUniversity of OsloUnknownMemory | Gene ExpressionNorway
-
Technological Centre of Nutrition and Health, SpainCompletedGene Expression | Cardiovascular FunctionSpain
-
Kurdistan Higher Council of Medical SpecialtiesActive, not recruitingGene Expression Profiling | Orthodentic AppliancesIraq
-
Blood Transfusion Centre of SloveniaCompletedMetabolomics | Gene Expression | Immunological StatusSlovenia
-
Pontificia Universidad Catolica de ChileUnknownLiver Transplantation | Gene Expression | Immunosuppression ConversionChile
-
University of BathMinistry of Education, TaiwanCompletedAdipose Tissue Gene Expression
-
Medical University of GrazCompletedNFAT Regulated Gene Expression in Tacrolimus Treated PatientsAustria
Clinical Trials on 3-days high fat diet
-
University of AdelaideCompletedDiabetes | Metabolic SyndromeAustralia
-
Chinese Academy of SciencesCompletedHealthy and Overweight/ Obesity MalesChina
-
Maastricht University Medical CenterCompleted
-
Rutgers, The State University of New JerseyCompleted
-
Zhejiang UniversityNational Natural Science Foundation of China; Chinese PLA General Hospital; National...Completed
-
Göteborg UniversitySahlgrenska University HospitalCompleted
-
University of Alabama at BirminghamSmartFoods, Inc.Completed
-
Laval UniversityActive, not recruiting
-
Tufts UniversityCompletedDyslipidemia | Impaired Glucose Tolerance
-
UCSF Benioff Children's Hospital OaklandNational Cattlemen's Beef AssociationCompletedHealthy | Cardiovascular Disease | Atherogenic DyslipidemiaUnited States